← All trials
NCT03326791
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2017
- Primary completion
- Oct 31, 2023
- Completion date
- Oct 31, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 800
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OsloLead sponsor
- University of OsloReponsible party - principal investigator
- University of OsloOverall official - principal investigator
- Government of NorwayCollaborator
- University of OsloCollaborator
- Norwegian Cancer SocietyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.